Sophiris Bio, Inc. Recorded Big Gain
Thu, Jan 02, 2020 at 05:30 PM
Sophiris Bio, Inc. (SPHS:NASDAQ) shot up at $0.5, representing a gain of 35.1%. On Wed 01 Jan 20, SPHS:NASDAQ hit a New 2-Week Intraday High of $0.4. From Tue 10 Dec 19, the stock recorded 35.71% Up Days and 33.33% Green Days
The share price of the company has been moving sideways in recent weeks.
About Sophiris Bio, Inc. (SPHS:NASDAQ)
Sophiris Bio Inc is a clinical-stage biopharmaceutical company. The Company is engaged in research and development of products for the treatment of urological diseases. It is currently developing PRX302 for treatment of benign prostatic hyperplasia.
Top 10 Gainers:
- Inpixon (INPX:NASDAQ), 201.83%
- DPW Holdings, Inc. (DPW:NYSEMKT), 101.65%
- Synthesis Energy Systems, Inc. (SES:NASDAQ), 100%
- Pulmatrix, Inc. (PULM:NASDAQ), 88.37%
- Outlook Therapeutics, Inc. (OTLK:NASDAQ), 48.31%
- Trillium Therapeutics Inc. (TRIL:NASDAQ), 44.66%
- Cassava Sciences, Inc. (SAVA:NASDAQ), 38.46%
- ToughBuilt Industries, Inc. (TBLT:NASDAQ), 37.45%
- Sophiris Bio, Inc. (SPHS:NASDAQ), 35.05%
- Aethlon Medical, Inc. (AEMD:NASDAQ), 29.8%